Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life
Authors:
- Esther N. OlivaEOEsther N. Oliva
- Francesco NobileFNFrancesco Nobile
- Giuliana AlimenaGAGiuliana Alimena
- Giorgina SpecchiaGSGiorgina Specchia
- Marco DanovaMDMarco Danova
- Bianca RovatiBRBianca Rovati
- Francesca RoncoFRFrancesca Ronco
- Stefana ImperaSIStefana Impera
- Antonio RisitanoARAntonio Risitano
- Caterina AlatiCACaterina Alati
- Massimo BrecciaMBMassimo Breccia
- Ida CarmosinoICIda Carmosino
- 6 April 2010
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 51 (6) , 1007-1014
Abstract
To evaluate efficacy, safety, changes in biological features, and quality of life (QoL) in low-risk anemic patients with MDS treated with darbepoetin alfa (DPO), 41 patients received DPO 150 microg weekly for 24 weeks. The dose was increased to 300 microg weekly in non-responsive patients. During treatment, 10/17 (59%) transfusion-dependent (TD) and 13/23 (56%) transfusion-free (TF) patients responded. In TF patients, Hb increased from 9.2 +/- 0.9 g/dL to 10.3 +/- 1.4 g/dL by 24 weeks (p = 0.004). The mean response duration was 22 weeks (95% CI: 19.7-24.0) in TF patients compared with 15.1 weeks (95% CI: 13.3-17.5) in TD patients. Response to treatment was associated with increases in QoL. Decreases in the percentage of apoptotic progenitor cells (p = 0.007) and CD34+ cells (p = 0.005) were observed. These results confirm previous studies demonstrating the safety and efficacy of DPO in anemic patients with MDS. Biological changes and improvement in QoL were associated with response. Adequate dosing is to be determined.Keywords
This publication has 23 references indexed in Scilit:
- Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)Blood, 2009
- Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic SyndromeJournal of Clinical Oncology, 2008
- Phase 2, single‐arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromesBritish Journal of Haematology, 2008
- Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated AnemiaJAMA, 2008
- Hematopoietic Growth Factors in the Treatment of Acquired Bone Marrow Failure StatesSeminars in Hematology, 2007
- Darbepoetin α for the treatment of anemia in patients with myelodysplastic syndromesCancer, 2006
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006
- High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II studyBritish Journal of Haematology, 2006
- Myelodysplasic syndromes: A comprehensive reviewBlood Reviews, 2005
- Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromesAnnals of Oncology, 2005